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An HTS FP assay able to selectively identify STAT3-DBD 
inhibitors
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News on: A high-throughput fluorescence polarization assay for discovering inhibitors targeting the DNA-binding do-
main of signal transducer and activator of transcription 3 (STAT3) by Shih et al. Oncotarget. 2018; 9:32690-32701. 
https://doi.org/10.18632/oncotarget.26013
Over the last two decades, signal transducer and 
activator of transcription 3 (STAT3) signaling pathway 
has been confirmed to play a pivotal role in initiating 
and sustaining pathological processes, and its inhibitors 
are currently under investigation for the treatment of 
oncologic, hematologic and chronic inflammatory 
diseases [1]. During this time, the target of STAT3 
drug discovery research has been strongly influenced 
by the clear relationship that phosphorylation of the 
Src homology 2 (SH2) domain significantly enhances 
homo-dimerization, and in turn increases translocation. 
This rational has led to the discovery and validation of 
a number of inhibitors able to abate STAT3 activity in 
a variety of settings. However, the targeting of the SH2 
phosphotyrosine binding site by small molecule inhibitors 
has met with very limited success in a clinical setting [2, 
3]. Since this failure could be attributed to the ability of 
STAT3 to translocate into the nucleus, and to be activated 
even in the absence of SH2 phosphorylation, Shih et al., 
in the paper published in this issue of Oncotarget, focused 
on inhibiting STAT3 DNA-binding domain (DBD) by 
targeting the DBD, as an alternative, and perhaps better, 
downstream target [4]. Nevertheless, the latter being a 
more challenging molecular target, only a limited amount 
of validated inhibitors have been taken forward. One 
of several significant hurdles associated with targeting 
STAT3/DNA binding is the lack of a well-validated high-
throughput evaluation assay [4] for the identification of 
small molecules. Currently, only EMSA and ELISA-based 
methods reliably characterize STAT3 DBD inhibitors.
To close this gap and enhance research efforts 
into finding STAT3/DNA inhibitors, Shih et al. reported 
a new practical biophysical assay – the fluorescence 
polarization (FP) competition assay. The assay, which 
utilizes a truncated STAT3127-688 construct as a target 
and Bodipy-DNA as the probe [4], can be used to identify 
potential STAT3 DBD inhibitors, coined here as the 
STAT3127-688:DNA FP assay [4]. To ensure its validity, 
the assay was tested using both unlabelled consensus 
and non-consensus double-stranded DNA sequences. 
One interesting aspect noted by Shih et al. was that the 
equilibrium of STAT3127-688:DNA interaction was 
reached after 14 hr and was reliable up to 48 hr. This 
then allows one to understand time-dependent activities 
of inhibitors in a cell-free environment [4]. The pilot 
screening run by Shih et al. determined IC50 of known 
STAT3 DBD small molecule inhibitors in a 96-well 
plate format; for compounds inS3-54, inS3-54A18 and 
niclosamide they were 21.3 ± 6.9 μM, 126 ± 39.7 μM and 
219 ± 43.4 μM after 24 hr, respectively.
Interesting to note, Shih et al. showed that the 
STAT3127-688:DNA FP assay can be conducted in 
parallel with another FP assay [4] designed to identify 
STAT3 SH2 domain inhibitors, as reported by Schust and 
Berg [5], thus helping to distinguish between the different 
mode(s) of action of an inhibition. As several of the 
available inhibitors evidenced a dual mechanism of action, 
this test, when undertaken concurrently in two halves of 
the same plate, identifies the relative contribution of each 
target domain. This can allow a more reliable selection 
between ligand’s alternative mode(s) of action within 
screening libraries.
In particular, the cell-free method described by 
this research team, if functional for Platinum-complex 
inhibitors which are recognized to alter the biological 
function of different targets [6], would be very helpful to 
rule out effects on upstream proteins or off-target effects.
Looking ahead, the STAT3127-688:DNA FP 
assay published by Shih et al. will aid in the bioactivity 
evaluation of STAT3 inhibitors in vitro, and will be 
extended to screen, with a simple protocol, molecules 
interacting with other members of the STAT family, 
including STAT1 and STAT5, both valid protein targets 
for drug discovery [4].
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